Annovis Bio, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Annovis Bio, Inc. (ANVS) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$6.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-13
- Annovis Bio, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$6.06M.
- Annovis Bio, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$5.16M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$6.06M 10-K · filed 2026-03-13 |
| 2024-12-31 | -$5.16M 10-K · filed 2026-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |